Immunotherapy: Is It Right For Me?

Coupling Cancer Therapies

Over the past several years, immunotherapy has been the latest hope in medical intervention. Personally, I am a big supporter of immunotherapy, especially coupled with Rife; we’ve found it to be a great addition for many people. The problem is that it simply doesn’t work for all cancers or all patients. There is a specific genetic test done to see if one qualifies. Also, insurance companies may require that one “fails” traditional chemotherapy prior to trying immunotherapy.

Immunotherapy, also called by its “old name”, biologic therapy, is a type of cancer treatment that, according to their website, “boosts the body’s natural defenses to fight cancer.” It doesn’t really do that. What it does is that it fools one’s T-cells to interrupt a specific cell receptor responsible to keep immune cells from attacking one’s own cells. This makes a lot of sense. Your own immune system is programmed so that it WON’T attack self-tissue. This is a good thing as it keeps us from literally destroying ourselves. However, cancer is self-tissue and this is one of the reasons our immune system has in recognizing it (the growing cancer) as an enemy.

Immunotherapy is a group of drugs that, in simplest terms, block that “turn-off switch” so our immune cells (specifically our T-cells) will attack the cancer. Again, the problem is that it simply doesn’t work on all types of cancer our on all people. However, it is an extremely promising approach.

Immunotherapy isn’t chemotherapy so it isn’t a “toxic” treatment. It isn’t without side effects though. Since it is turning-off self-tissue recognition of immune cells, one can exhibit symptoms/disorders of just about any disease that ends in an “itis”. Colitis is probably the most common issue but any autoimmune disorder is possible. The good thing is that a few months following discontinuation, usually these symptoms abate.

Coupling the immunotherapy drug with Rife therapy, in my opinion, is the BEST. I believe that the Rife helps both chemotherapy AND/OR immunotherapy TARGET the cancer MUCH better!

One other problem with immunotherapy (as well as CAR T-Cell Therapy discussed next) is that it requires a healthy and strong patient immune system. If one has been already revenged by chemotherapy and radiation, success may be limited.

Currently, an independent researcher is self-funding a project at Mayo Clinic in Rochester, MN to couple immunotherapy with OUR PRODUCT – Evolv Immune (a polysaccharide immune stimulant – see chapter 5) and Evolv Entourage (a water soluble, nano CBD oil). This is SUPER exciting.

Some current immunotherapy drugs:

• Ipilimumab (Yervoy)
• Nivolumab (Opdivo)
• Pembrolizumab (Keytruda)
• Atezolizumab (Tecentriq)
• Avelumab (Bavencio)
• Durvalumab (Imfinzi)

CAR-T-Cell Therapy

A novel, emerging, type of immunotherapy approach is called adoptive cell transfer (ACT): collecting and using patients’ own immune cells to treat their cancer. There are several types of ACT, but the one that has advanced the furthest in clinical development is called CAR T-cell therapy.

In 2017, two CAR T-cell therapies were approved by the Food and Drug Administration, one for the treatment of children with acute lymphoblastic leukemia (ALL) and the other for adults with advanced lymphomas.

CAR T cells are the equivalent of “giving patients a living drug,” explained Renier J. Brentjens, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center in New York, an early leader in the CAR T-cell field.

As its name implies, the backbone of CAR T-cell therapy is our immune T-cells, which are a key killer cell of the immune system because of their critical role in orchestrating the immune response and destroying cells infected by pathogens. The therapy requires drawing blood from patients and separating out the T-cells. Next, using a disarmed virus, the T-cells are genetically engineered to produce receptors on their surface called chimeric antigen receptors, or CARs.

These new receptors are “synthetic molecules, they don’t exist naturally,” explained Carl June, M.D., of the University of Pennsylvania Abramson Cancer Center, during a recent presentation on CAR T cells at the National Institutes of Health campus.

These new receptors allow the T-cells to recognize and attach to a specific protein, or antigen, on tumor cells, thereby helping one’s own immune system attack the cancer. This is also a very promising therapy but it also has some drawbacks that mainly involve cost. Currently, insurance is not paying for this therapy and costs range from 1.5 to 2.5 million per attempt. I created a video outlining this that you can view here:

Get your hard-copy of Stop Fighting Cancer & Start Treating the Cause to learn more about how to treat cancer with alternative medicine, and for even more in-depth education and help, check out Dr. Conners’ Stop Fighting Cancer COURSE. 

Excerpt taken from Chapter One of Stop Fighting Cancer & Start Treating the Cause.